In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF (NYSEARCA: XBI) and the Nasdaq Biotechnology Index (NASDAQ: IBB) struggled to find their footing in late March 2026, dropping
The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the company’s market capitalization, was triggered by a "perfect storm" of positive regulatory developments and breakthrough clinical
March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of Lifyorli™ (relacorilant) for platinum-resistant ovarian cancer (PROC). This approval, coming four months ahead of its scheduled PDUFA date, marks Corcept's transition from a niche endocrinology player into [...]
By Finterra Editorial TeamMarch 18, 2026 Introduction In the high-stakes world of global alternative asset management, one name looms larger than the rest: Blackstone Inc. (NYSE: BX). As of March 18, 2026, Blackstone has solidified its position as the first alternative manager to cross the $1.3 trillion threshold in Assets Under Management (AUM). No longer [...]
As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq: XENE). Long a favorite of biotech specialists for its deep expertise in ion-channel biology, Xenon has officially transitioned from a "high-potential" R&D firm to a "pre-commercial" titan following [...]
Duquesne Family Office's billionaire boss meaningfully pared down two high-flying stocks in the fourth quarter and made a $301 million wager on a popular sector-based exchange-traded fund (ETF).
As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent history, the company has spent the better part of the 2020s shedding the skin of its predecessor identities—Mylan and Pfizer’s Upjohn [...]
As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the 2020 merger of Mylan and Pfizer’s Upjohn division, struggling to find its footing in a deflationary generic drug market. However, [...]
The application was based on data from a late-stage trial in which TEV-'749 administered as a once-monthly subcutaneous injection demonstrated an efficacy and safety profile consistent with currently available olanzapine formulations.
February 10, 2026 Introduction As of February 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a pivotal juncture. Five years after its high-profile inception, the company has shed its skin as a debt-laden conglomerate of legacy brands to emerge as a leaner, more focused player in the specialty pharmaceutical space. For years, investors viewed Viatris [...]
